178
Participants
Start Date
July 31, 2013
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
COL-1620
The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent \[%\] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
Gonadotropin-releasing hormone (GnRH) analogue
Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
Follicle-stimulating hormone (FSH)
Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
Human Chorionic Gonadotropin (hCG)
Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
Research site, Fujimino
Research site, Kobe
Research site, Osaka
Research site, Sagamihara
Research site, Yokohama, Kanagawa
Merck KGaA, Darmstadt, Germany
INDUSTRY